Promising new biomarkers of kidney disease in heart failure

When kidneys gradually fail to filter waste from the blood, dangerous levels of fluid accumulate that put stress on the heart. Impaired kidney function leads to the development and progression of heart failure. Biomarkers could potentially be implemented in the diagnosis and risk stratification of patients with kidney and heart failure.

Discover new kidney & heart biomarker assays from Biomedica

ELISA kits for clinical & preclinical research

FGF23 ▪ Endostatin ▪ Vanin-1 ▪ Periostin ▪ Big ET-1 ▪ LRG ▪ NT-proANP ▪ NT-proBNP

Why Biomedica immunoassays?

• Full validation in all matrices
• Reference values provided
• Ready to use calibrators & controls
• Low sample volumes
• Trusted – widely cited in over 1700 citations

High specificity – only measures the analyte of interest. The Biomedica ELISA kits offer unique specificity using propriety epitope-mapped antibodies.

Learn more

Big Endothelin-1 (Big ET-1) is the precursor of biologically active Endothelin-1 (ET-1), the most potent vasoconstrictor. Elevated levels of BigET-1 provide an independent risk factor for adverse outcomes in patients with heart failure. BigET-1 circulates in equimolar amounts as ET-1 and has proven to be a more reliable biomarker due to its longer half-life.

Endostatin is an angiogenesis inhibitor. Its dysregulation plays a crucial role in the pathogenesis of cardiovascular and renal diseases. Circulating Endostatin is significantly increased in patients with heart and kidney failure.

Fibroblast growth factor-23 (FGF23) is a hormone that inhibits phosphate reabsorption and Vitamin D synthesis. Patients with kidney disease suffer from cardiovascular disease, which is triggered by FGF23 and phosphate, both cardiovascular toxins. High circulating FGF23 levels have been associated with adverse cardiovascular outcomes such as heart failure and arrhythmias.

Leucine-riche alpha-2-glyoprotein (LRG) plays a crucial role in pathogenic ocular neovascularization. LRG is also related to cardiovascular disease, diabetes, inflammatory disorders, and cancer. Circulating plasma levels of LRG have accurately been identified in patients with heart failure stronger than BNP, independent of age, sex, and creatinine.   

Vanin-1 is an epithelial ectoenzyme which is highly expressed in renal tubular epithelial cells. Studies have shown that Vanin-1 is an early biomarker of renal tubular damage in drug-induced acute kidney injury.

References

1. Gergei I, Krämer BK, Scharnagl H, Stojakovic T, März W. Renal function, N-terminal Pro-B-Type natriuretic peptide, propeptide big-endothelin and patients with heart failure and preserved ejection fraction. Peptides. 2019;111:112-117.
2. Li M, Popovic Z, Chu C, Krämer BK, Hocher B. Endostatin in renal and cardiovascular diseases. Kidney Dis (Basel). 2021;7(6):468-481.
3. Vogt I, Haffner D, Leifheit-Nestler M. Fgf23 and phosphate–cardiovascular toxins in ckd. Toxins (Basel). 2019;11(11):647.
4. Shin M, Mun S, Park SH, Lee J, Kang HG. Serum biomarker discovery related to pathogenesis in acute coronary syndrome by proteomic approach. Biosci Rep. 2021;41(6):BSR20210344.
5. Hosohata K, Ando H, Fujimura A. Urinary vanin-1 as a novel biomarker for early detection of drug-induced acute kidney injury. J Pharmacol Exp Ther. 2012;341(3):656-662.